Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

It is likely that the addition of daratumumab (Darzalex) to the lenalidomide (Revlimid)/dexamethasone backbone will lead to a significant progression-free and overall survival benefit for patients with multiple myeloma, Voorhees explains. This regimen is also associated with high response rates. In a study with this regimen in the relapse setting, at least three-fourths of patients achieved a very good partial response and a little over 40% achieved a complete response or better, he adds. These numbers will likely be higher in newly diagnosed disease.

The addition of elotuzumab (Empliciti) and ixazomib (Ninlaro) to the field are overall well tolerated agents that provide additional options for patients.